Oncternal Therapeutics, Inc.
NASDAQ: ONCT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- James B. Breitmeyer
- Employees
- 27
- Headquarters
- San Diego, United States
- IPO year
- 2004
- Market cap
- $1.6M
- Website
- https://www.oncternal.com
Loading ONCT…
Loading profile data…Frequently asked questions about ONCT
What does Oncternal Therapeutics, Inc. (ONCT) do?
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating cancer treatments for diseases where current medical options are insufficient. Its clinical-stage portfolio features zilovertamab, a humanized monoclonal antibody designed to bind to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216,...
Where does ONCT trade?
Oncternal Therapeutics, Inc. (ONCT) trades on the NASDAQ Capital Market.
What sector is ONCT in?
Oncternal Therapeutics, Inc. (ONCT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Oncternal Therapeutics, Inc.?
James B. Breitmeyer is the chief executive officer of Oncternal Therapeutics, Inc. (ONCT).
Where is Oncternal Therapeutics, Inc. headquartered?
Oncternal Therapeutics, Inc. is headquartered in United States.
Does ONCT pay a dividend?
Oncternal Therapeutics, Inc. (ONCT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ONCT go public?
Oncternal Therapeutics, Inc. (ONCT) completed its initial public offering in 2004.